Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROCOMP vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
The combination of acetaminophen, caffeine, and isometheptene exerts its effects through multiple mechanisms: acetaminophen inhibits cyclooxygenase (COX) enzymes in the CNS, reducing prostaglandin synthesis and pain; caffeine is a non-selective adenosine receptor antagonist that enhances pain relief; isometheptene is a sympathomimetic amine that constricts dilated cerebral blood vessels.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Treatment of tension-type headache,Treatment of migraine headache (acute)
Prevention of pregnancy (FDA-approved)
50 mg orally once daily
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Terminal elimination half-life: 12-18 hours (mean 15 hours). Steady-state reached within 3-5 days; clinical effect correlates with trough concentrations.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Acetaminophen: primarily metabolized by glucuronidation and sulfation in the liver with minor CYP2E1-mediated oxidation to a hepatotoxic metabolite (NAPQI). Caffeine: hepatic metabolism via CYP1A2 (demethylation to paraxanthine). Isometheptene: not well characterized; likely hepatic metabolism.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Renal: 60% as unchanged drug; biliary/fecal: 30% as metabolites; total recovery ~90% in urine and feces within 72 hours.
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
98% bound primarily to albumin, with minor binding to alpha-1-acid glycoprotein.
~99% bound to serum albumin and sex hormone-binding globulin.
0.3-0.5 L/kg (mean 0.4 L/kg). Low Vd indicates limited tissue distribution, predominantly in extracellular fluid.
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral: 85-90% (first-pass metabolism minimal); IM: 95-100%; rectal: 50-60% (variable).
Oral: ~70% due to first-pass metabolism.
No adjustment required for GFR >30 m L/min; not recommended if GFR <30 m L/min due to limited data
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose to 25 mg once daily. Child-Pugh C: not recommended.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Not established for patients under 18 years of age
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Start at 25 mg once daily; titrate cautiously based on tolerability
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
No FDA boxed warning exists for Procomp.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Hepatotoxicity with acetaminophen overdose (dose-dependent); limit daily acetaminophen intake to ≤4000 mg (or less if hepatic impairment).,Caffeine may exacerbate anxiety, insomnia, or cardiac arrhythmias; limit caffeine intake from other sources.,Isometheptene may increase blood pressure and heart rate; caution in hypertension, cardiovascular disease, or hyperthyroidism.,May cause dizziness or drowsiness; avoid driving or operating machinery until effects are known.
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Hypersensitivity to acetaminophen, caffeine, isometheptene, or any component,Severe hypertension,Coronary artery disease,Peripheral vascular disease,Concomitant use or within 14 days of monoamine oxidase inhibitors (MAOIs),Angle-closure glaucoma
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
Avoid alcohol. May cause photosensitivity, so limit exposure to sunlight. Take with food if gastrointestinal upset occurs. Grapefruit juice may increase prochlorperazine levels; avoid excessive consumption.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
First trimester: Use of PROCOMP has been associated with increased risk of major congenital malformations, including neural tube defects, orofacial clefts, and cardiovascular anomalies. Second and third trimesters: Chronic exposure may lead to fetal growth restriction, preterm birth, and neonatal withdrawal syndrome. Risk is dose-dependent and highest with first-trimester exposure.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
PROCOMP and its active metabolite are excreted into human breast milk with a milk-to-plasma (M/P) ratio of 0.8–1.2. According to AAP, potential adverse effects include sedation, poor feeding, and hypotonia in breastfed infants. Caution advised; consider risk versus benefit.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
During pregnancy, increased plasma volume and enhanced hepatic metabolism (CYP3A4 induction) may reduce PROCOMP concentrations by 30-50%. Dose adjustments may be required to maintain therapeutic efficacy; frequent therapeutic drug monitoring recommended. No specific dose adjustment guidelines exist; individualize based on clinical response and drug levels.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
PROCOMP (prochlorperazine) is a phenothiazine antiemetic and antipsychotic. Use caution in elderly patients due to increased risk of hypotension, sedation, and extrapyramidal symptoms. Avoid use in patients with QT prolongation. Monitor liver function tests periodically. Can cause neuroleptic malignant syndrome; discontinue if fever, rigidity, or altered mental status occurs.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Avoid alcohol and CNS depressants as they may increase sedation.,Report symptoms of involuntary muscle movements, tardive dyskinesia, or jaundice immediately.,Rise slowly from sitting or lying position to prevent dizziness.,Do not drive or operate heavy machinery until you know how this medication affects you.,Take exactly as prescribed; do not double doses if missed.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROCOMP vs AFIRMELLE, answered by our medical review team.
PROCOMP is a Oral Contraceptive that works by The combination of acetaminophen, caffeine, and isometheptene exerts its effects through multiple mechanisms: acetaminophen inhibits cyclooxygenase (COX) enzymes in the CNS, reducing prostaglandin synthesis and pain; caffeine is a non-selective adenosine receptor antagonist that enhances pain relief; isometheptene is a sympathomimetic amine that constricts dilated cerebral blood vessels.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROCOMP and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROCOMP is: 50 mg orally once daily. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROCOMP and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROCOMP is classified as Category C. First trimester: Use of PROCOMP has been associated with increased risk of major congenital malformations, including neural tube defects, orofacial clefts, and cardiovascular anoma. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.